Pbc 3
PBC3 was a multi-centre randomized clinical trial conducted in six European hospitals. Between 1 Jan. 1983 and 1 Jan. 1987, 349 patients with the liver disease primary biliary cirrhosis (PBC) were randomized to either treatment with Cyclosporin A (CyA, 176 patients) or placebo (173 patients). The purpose of the trial was to study the effect of treatment on the survival time. However, during the course of the trial an increased use of liver transplantation for patients with this disease made the investigators redefine the main response variable to be time to ``failure of medical treatment'' defined as either death or liver transplantation. Patients were then followed from randomization until treatment failure, drop-out or 1 Jan, 1989; 61 patients died (CyA: 30, placebo: 31), another 29 were transplanted (CyA: 14, placebo: 15) and 4 patients were lost to follow-up before 1 Jan. 1989. At entry a number of clinical, biochemical and histological variables, including serum bilirubin, serum albumin, sex, age were recorded. List of variables: ptno patient identification unit hospital (1: Hvidovre, 2: London, 3: Copenhagen, 4: Barcelona, 5: Munich, 6: Lyon) tment treatment (0: placebo, 1: CyA) sex (1: males, 0: females) age years stage histological stage (1, 2, 3, 4) gibleed previous gastrointestinal bleeding (1: yes, 0: no) crea creatinine (micromoles/L) alb albumin (g/L) bili bilirubin (micromoles/L) alkph alkaline phosphatase (IU/L) asptr aspartate transaminase (IU/L) weight body weight (kg) days observation time (days) status status at exit (0: censored, 1: liver transplantation, 2 : dead)
The dataset
Scripts for loading the dataset
Programs related to Pbc 3
Figure 1.1.1: R-source SAS-source Stata-source (fig-pbc3-ch1intro-KMtreat) | |
Table 1.3.2: R-source SAS-source Stata-source (tab-pbc3-ch1link-bili) | |
Figure 1.3.6: R-source SAS-source Stata-source (fig-pbc3-ch1link-KMbili) | |
Figure 1.3.7: R-source SAS-source Stata-source (fig-pbc3-ch1link-hazratbili) | |
Table 3.1.16: R-source SAS-source (tab-pbc3-means) | |
Table 3.1.17: R-source SAS-source (tab-pbc3-percentages) | |
Figure 3.1.6: R-source SAS-source (fig-pbc3-ch3surv2sample-KMtreat) | |
Figure 3.1.7: R-source SAS-source (fig-pbc3-ch3surv2sample-modelcheck) | |
Figure 3.1.8: R-source SAS-source (fig-pbc3-ch3surv2sample-pseudo) | |
Table 3.1.18: R-source (tab-ch3logrank-2) | |
Table 3.1.19: R-source SAS-source (tab-pbc3-ch3-treat) | |
Figure 3.2.6: R-source SAS-source (fig-pbc3-ch3-KMbili) | |
Figure 3.2.7: R-source SAS-source (fig-pbc3-ch3survksample-modelcheck) | |
Figure 3.2.8: R-source SAS-source (fig-pbc3-ch3survksample-pseudo) | |
Table 3.2.14: R-source SAS-source (tab-pbc3-ch3-ksamplebili) | |
Table 4.1.3: R-source SAS-source (tab-ch4-bilitab) | |
Figure 4.1.17: R-source SAS-source (fig-pbc-ch4-pseudobiliscatter) | |
Figure 4.1.18: R-source SAS-source (fig-pbc-ch4-pseudobiliscatter-cloglog) | |
Figure 4.1.19: R-source SAS-source (fig-pbc-ch4-pseudobilires) | |
Figure 4.1.20: R-source SAS-source (fig-ch4-bvslogbili) | |
Figure 4.1.21: R-source SAS-source (fig-pbc-ch4-pseudologbiliscatter) | |
Figure 4.1.22: R-source SAS-source (fig-pbc-ch4-pseudologbiliscatter-cloglog) | |
Figure 4.1.23: R-source SAS-source (fig-pbc-ch4-pseudologbilires) | |
Figure 4.1.24: R-source SAS-source (fig-ch4-logbilidiagnosticsvslogbili) | |
Figure 4.1.25: R-source SAS-source (fig-ch4-bilidiagnosticsvsbili) | |
Figure 4.2.2: R-source SAS-source Stata-source (fig-ch4pwchfig) | |
Figure 4.2.3: R-source SAS-source (fig-ch4-pwchpseudobiliscatter) | |
Figure 4.2.4: R-source SAS-source (fig-ch4-pwchpseudoLogbiliscatter) | |
Figure 4.2.5: R-source SAS-source (fig-ch4splinefig) | |
Figure 4.2.6: R-source SAS-source (fig-ch4-influential-bilisquared) | |
Table 4.2.1: R-source SAS-source (tab-ch4fractional) | |
Figure 4.2.7: R-source SAS-source (fig-ch4fractional) | |
Figure 4.2.8: R-source SAS-source (fig-ch4zeroexpfig) | |
Table 4.2.2: R-source SAS-source (tab-ch4zeroexptab) | |
Table 5.1.8: R-source SAS-source (tab-ch5-pbc-strat) | |
Table 5.1.10: R-source SAS-source (tab-ch5bilimeans) | |
Table 5.1.11: R-source SAS-source (tab-ch5treatment-bili) | |
Figure 5.1.9: R-source SAS-source (fig-ch5-fracnoint) | |
Figure 5.1.10: R-source SAS-source (fig-ch5-normrangenoint) | |
Figure 5.2.2: R-source SAS-source (fig-ch5-fracinteract) | |
Figure 5.2.3: R-source SAS-source (fig-ch5-normrangeinteract) | |
Figure 5.2.4: R-source SAS-source (fig-ch5-fractreat) | |
Figure 5.2.5: R-source SAS-source (fig-ch5-normrangetreat) | |
Table 5.2.12: R-source SAS-source (tab-ch5treatment-biliinteract) | |
Table 6.2.16: R-source SAS-source (tab-tmentstage) | |
Table 6.2.17: R-source SAS-source (tab-tmentother) | |
Table 6.2.18: R-source SAS-source (tab-tmentresults) | |
Table 6.2.19: R-source SAS-source (tab-ch6pbc-prophaz) | |
Figure 6.2.14: R-source SAS-source (fig-ch6treat-baseline) | |
Table 6.2.20: R-source SAS-source (tab-ch6-pbclinearity) | |
Figure 6.2.15: R-source SAS-source (fig-ch6pseudo-alb) | |
Figure 6.2.16: R-source SAS-source (fig-ch6pseudo-logbili) | |
Table 6.2.21: R-source SAS-source (tab-pbcfinal) | |
Figure 6.2.17: R-source SAS-source (fig-ch6pseudo-logalkph) | |
Figure 6.2.18: R-source SAS-source (fig-ch6pseudo-logamtr) | |
Figure 6.2.19: R-source SAS-source (fig-ch6pseudo-age) | |
Figure 6.2.20: R-source SAS-source (fig-albdiag) |